Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 03.09.20 with a price of €105.70. With a performance of -4.98%, the SELL prediction for Alnylam Pharmace. by Biotechhunter was down slightly. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 6.396% | 6.396% | -49.682% | 12.485% |
| iShares Core DAX® | 2.573% | 5.333% | 8.273% | 63.863% |
| iShares Nasdaq 100 | 4.858% | 0.449% | 27.079% | 86.273% |
| iShares Nikkei 225® | 5.590% | -0.586% | 48.553% | 78.351% |
| iShares S&P 500 | 3.250% | 2.500% | 23.351% | 68.711% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.


